Investigating the Safety and Efficacy of Anti-CD7 CAR-T Cell Immunotherapy in Patients With Relapse and Refractory T-cell Acute Lymphoblastic Leukemia or T Lymphoblastic Lymphoma
Latest Information Update: 30 Nov 2022
Price :
$35 *
At a glance
- Drugs GC 027 (Primary)
- Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 23 Nov 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 May 2021 Planned initiation date changed from 1 May 2021 to 1 Dec 2021.
- 29 Apr 2021 New trial record